Rivastigmine vs placebo
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
- Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyOR 3.21 [0.36, 28.88]3 studies · 831 participantsVery low